Monoclonal antibodies targeting cancer: 'Magic bullets' or just the trigger?

Breast Cancer Research

Volumn 3, Issue 2, 2001, Pages 86-90

  Eccles, S A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Antibody dependent cellular cytotoxicity; Fc receptors; Herceptin; Monoclonal antibody; Rituxan

Indexed keywords

ALEMTUZUMAB; ANTISENSE OLIGONUCLEOTIDE; CD20 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; RITUXIMAB; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE CONSTRUCT; GENETIC ENGINEERING; HOST CELL; HUMAN; MOUSE; NONHUMAN; ONCOGENE NEU; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, FC;

EID: 0035057790     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr276     Document Type: Article

References (27)

1. Monoclonal antibody therapy for solid tumors
2. Monoclonal antibody therapy for cancer
3. Anticancer agents targeting signalling molecules and cancer cell environment: Challenges for drug development?
4. Tyrosine kinase signalling in breast cancer
5. C-erbB-2 as a target for immunotherapy
6. Nonclinical studies addressing the mechanism of action of action of Trastuzumab (Herceptin)
7. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2
8. Antibody-induced inhibition of growth of EGFR overexpressing tumours occurs in the absence of receptor down-regulation
9. Preclinical and Phase I and II trials of Rituximab
10. Differentiation or immune destruction: Two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor
11. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
12. The IgG Fc receptor family
13. Pharmacokinetic studies of radiolabelled rat monoclonal antibodies recognising syngeneic sarcoma antigens: II. Effect of age and host immune status
14. Differential in vitro and in vivo antitumour effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B cell lymphomas
15. Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors
16. HER2 overexpressing tumor cells
17. Antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody MDX-210
18. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumor cells
19. Isolation and characterisation of an anti-CD16 single chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16- dependent tumor cytolysis
20. The immunology and immunotherapy of breast cancer: An update
21. The IgG Fc contains distinct Fc receptor (FcR) binding sites: The leukocyte receptors FcγR1 and FcγrIIa bind to a region in the Fc distinct from that recognised by neonatal FcR and protein A
22. Fcγ receptor IIB on follicular dendritic cells regulates the B cell recall response
23. Variant genotypes of the low affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations
24. The IgG Fc receptor FcγRIIB is a target for deregulation by chromosomal translocation in malignant lymphoma
25. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies
26. HER2/neu tyrosine kinases in vitro and in vivo
27. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: Role as anti-cancer agents